This is unpublished
lab
News

New study aims to evaluate a novel pediatric TB diagnostic tool and treatment response

August 30, 2024
Pinned
Back to top

SEATRAC member and Department of Global Health principal investigator Dr. Sylvia LaCourse and team have begun a new five-year study titled CRISPR-TB for pediatric TB diagnosis and treatment response” funded by the National Institutes of Health will support an evaluation of a CRISPR-based technology to target and detect Mycobacterium tuberculosis cell-free DNA (cfDNA). 

The study leverages an existing collaboration between KEMRI CRDR who leads the clinical cohorts, while the Hu Lab will lead the CRISPR-TB platform optimization and testing of samples. The UW GWACh team led by Dr. LaCourse will provide oversight for the study design, execution, and analysis.

Find full announcement from Gloabal WACh: New study aims to evaluate a novel pediatric TB diagnostic tool and treatment response | Global WACh (washington.edu)

Recent News

lab
1 week ago
Necessary components of a successful TB vaccine? SEATRAC awa…
lab
1 week ago
Author John Green wants you to care about TB
who logo
1 week 4 days ago
WHO Global TUBERCULOSIS REPORT 2024